Conduit and Charles River to evaluate AZD1656 in SLE model
Conduit Pharmaceuticals has announced a partnership with Charles River Laboratories to assess AZD1656 as well as its derivatives in a Systemic Lupus Erythematosus (SLE) model.
Conduit Pharmaceuticals has announced a partnership with Charles River Laboratories to assess AZD1656 as well as its derivatives in a Systemic Lupus Erythematosus (SLE) model.
UK-based biotechnology company ExpressionEdits has announced a partnership and licensing agreement with Boehringer Ingelheim for optimising the expression of gene therapies.
The US Food and Drug Administration (FDA) has accepted to review Regeneron Pharmaceuticals’ resubmitted biologics license application (BLA) for linvoseltamab to treat adults with relapsed/refractory (R/R) multiple myeloma (MM).
Radiopharmaceutical company AdvanCell has expanded its partnership with Eli Lilly and Company to advance targeted alpha therapies for the treatment of cancer.
Norgine Pharmaceuticals has launched Pedmarqsi (sodium thiosulfate injection) commercially in Germany.
Essential Pharma and Clinigen have announced their Japan-Asia Pacific (JAPAC) collaboration expansion to improve patient access to four therapies in Korea and Japan.
DEBRA Research and LEO Pharma have announced a non-exclusive strategic collaboration aiming to improve scouting capabilities and offer extra capacity to propel the development of therapies for Epidermolysis Bullosa (EB).
The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of Auron Therapeutics’ oral KAT2A/B degrader, AUTX-703, allowing it to progress through clinical development for haematological malignancies.
BioNTech has completed the previously announced acquisition of biotechnology company Biotheus for $800m, a move that strengthens its oncology strategy.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Bristol Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of unresectable or advanced hepatocellular carcinoma (HCC) in adults.